

STABILIS PHARMA INC.
BALANCE SHEET AS AT MARCH 31, 2019

		Amount in USD 31-Mar-19	Amount in USD 31-Mar-18
A ASSETS			
I Current assets			
(a) Financial assets			
(i) Cash and cash equivalents	1	1,819	2,119
(ii) Other financial assets	2	2,877	2,876
Total current assets		4,696	4,995
TOTAL ASSETS		4,696	4,995
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	3	1,000	1,000
(b) Other equity	4	1,164	521
Total Equity		2,164	1,521
II Liabilities			
1 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	5	-	3,474
(ii) Other financial liabilities	6	2,533	-
Total current liabilities		2,533	3,474
TOTAL EQUITY AND LIABILITIES		4,696	4,995

STABILIS PHARMA INC.
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2019

Particulars	Note No.	Amount in USD	
		31-Mar-19	31-Mar-18
1 Revenue from operations		-	-
2 Other Income		-	-
3 Total Revenue (1+2)		<u>-</u>	<u>-</u>
4 Expenses			
(a) Finance costs	7	300	365
(b) Other expenses	8	(2,500)	3,040
Total expenses		<u>(2,200)</u>	<u>3,405</u>
5 Profit / (Loss) before exceptional items and taxes (3-4)		<u>2,200</u>	<u>(3,405)</u>
6 Exceptional Item		-	-
7 Profit / (Loss) before taxes (5+6)		<u>2,200</u>	<u>(3,405)</u>
8 Tax Expense:			
(1) Current tax		1,558	-
(2) Deferred tax		-	-
Total tax expenses		<u>1,558</u>	<u>-</u>
VII Profit / (Loss) for the year after tax		<u>643</u>	<u>(3,405)</u>

STABILIS PHARMA INC.
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED MARCH 31, 2019

(A) Equity share capital

Particulars	Amount in USD
Balance as at March 31, 2017	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2018	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2019	1,000

(B) Other equity

Particulars	Share application money pending allotment	Reserves and surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2017	-	3,926	-	3,926.00
Profit/loss for the year		(3,405)		(3,405)
Other comprehensive income for the year (net of tax)		-		-
Balance as at March 31, 2018	-	521	-	521
Profit/loss for the year		643		643
Other comprehensive income for the year (net of tax)		-		-
Balance as at March 31, 2019	-	1,164	-	1,164

STABILIS PHARMA INC.

Notes forming part of financial statement

Note

No.

1	Cash and cash equivalents	Amount in USD	
		31-Mar-19	31-Mar-18
	Particulars		
	Cash in hand		
	Balances with banks:		
	In current accounts	1,819	2,119
	Total	1,819	2,119
2	Other financial assets	Amount in USD	
	Particulars	31-Mar-19	31-Mar-18
	Advances to related parties	2,877	2,876
	Total	2,877	2,876
3	Share capital	Amount in USD	
	Particulars	31-Mar-19	31-Mar-18
	Issued, subscribed and fully paid-up		
	Equity share capital	1,000	1,000
	Total	1,000	1,000
4	Reserves and surplus	Amount in USD	
	Particulars	31-Mar-19	31-Mar-18
	Surplus in statement of profit and loss		
	Opening balance	521	3,926
	Add: Profit / (Loss) for the year	643	(3,405)
	Closing balance	1,164	521
	Total	1,164	521
5	Trade payables	Amount in USD	
	Particulars	31-Mar-19	31-Mar-18
	Trade payable	-	3,474
	Total	-	3,474
6	Other Current financial Liabilities	Amount in USD	
	Particulars	31-Mar-19	31-Mar-18
	Payable to group entities	2,533	-
	Total	2,533	-

STABILIS PHARMA INC.
Notes forming part of financial statement

Note

No.

7	Finance cost	Amount in USD	
		31-Mar-19	31-Mar-18
	Particulars		
	Bank charges	300	365
	Total	300	365

8	Other expenses	Amount in USD	
		31-Mar-19	31-Mar-18
	Particulars		
	Rates & Taxes	-	1,290
	Payment to Auditors - For Statutory Audit	(2,500)	1,750
	Total	(2,500)	3,040